PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells

Chuchu Qiao1, Hongyan Qian2, Jue Wang1, Tingting Zhao1, Pengyu Ma1, Sicen Wang1, Tao Zhang1*, Xinshe Liu2*

1 School of Pharmacy, Xi’an Jiaotong University Health Science Center, Xi’an, ShaanXi, China, 2 School of Forensic Science and Medicine, Xi’an Jiaotong University Health Science Center, Xi’an, ShaanXi, China

* lxins@xjtu.edu.cn (XL); taozhang@xjtu.edu.cn (TZ)

Abstract

Fibroblast growth factor receptors (FGFRs) are frequently altered in a variety of human cancer cells and are overexpressed in hepatocellular carcinoma (HCC). Several literatures have proven that they are efficacious for HCC therapy, however, the underlying mechanism remains unclear. Here, we found FGFR4 was overexpressed in HCC cell lines HepG2 and Hep3B and we used PD173074, an FGFR4 inhibitor, to explore the role of FGFR4 and its underlying mechanism in these cell lines. The results showed that PD173074 significantly arrested HepG2 and Hep3B cells in G1 phase and inhibited cell proliferation. Furthermore, Western blot analysis revealed that PD173074 decreased the levels of P-FRS2α, P-ERK, CDK2, cyclin E and NF-κB (p65) in the nucleus while it increased the levels of ubiquitin and CUL3, an E3 ubiquitin ligase which involves in cyclin E degradation. Meanwhile, the data from RT-qPCR showed that PD173074 also decreased miR-141 level. In conclusion, these results suggest that FGFR4 is involved in HCC by ERK/CUL3/cyclin E signaling pathway, and the finding may provide a potential theoretical basis for treatment by targeting FGFR4 in HCC.

Introduction

The fibroblast growth factor receptors (FGFRs) belong to the family of receptor tyrosine kinases and the activation of these receptors by their high-affinity ligand FGF can activate their substrate-FGFR substrate 2 (FRS2) and, in turn, activate mitogen-activated protein kinase (MAPK) pathway [1]. Although the FGFR pathway plays a fundamental role in the organogenesis of the nervous system, tissue repair and inflammation, 7.1% of all tumor types have genetic alterations in the FGF-FGFR axis [2]. FGFR4 in the tumor tissues is significantly higher than that in normal liver tissues, and it is strongly associated with a higher TNM stage (T: tumor, N: lymph nodes, M: metastasis). In other words, higher FGFR4 expression results in worse prognosis and its inhibition reduces hepatocellular carcinoma (HCC) aggressiveness [3,4]. Aberrant FGF19 signaling through FGFR4 has been identified as an oncogenic driver in a subset of patients with HCC [5,6]. Work to date provides strong evidence that overexpressed
FGFRs affect the cell cycle machinery via cyclin D and blocking these receptors is efficacious for breast cancer therapy [7]. However, how FGFR4 promotes tumorigenesis of HCC remains unclear.

The cell cycle is a fundamental and irreversible process of growth and development of life, and a critically and tightly regulated step is the transition from G1 to S in which lots of regulators are involved [8]. As one key regulator in G1/S transition, cyclin E, a G1 cyclins, binds to CDK2 and then forms the cyclin E/CDK2 complex which phosphorylates a wide array of substrates to drive G1/S phase transition [9]. Further studies suggest that cyclin E activation is dependent upon the activation of the MAPK pathway following mitogenic stimulation [10,11], and lots of researchers have found that, compared with normal tissue, cyclin E is highly expressed in most liver cancers [12].

The ubiquitin-dependent proteolytic pathway is the major cellular proteolysis pathway and is responsible for the degradation of proteins which are involved in the cell cycle regulation. This complex pathway consists of three major enzymes: E1 (or ubiquitin-activating enzyme), E2 (or ubiquitin-conjugating enzyme) and E3 (or ubiquitin ligase) [13]. Current studies have proven that mammalian CUL1 (cullin 1) and CUL3, members of the E3 ligase family, are implicated in cyclin E degradation [14,15]. Furthermore, an in vitro study shows that CUL3 ubiquitinates cyclin E in a transient transfection system and another in vivo research demonstrates that knockout of the CUL3 gene in mice causes the increase of cyclin E protein [16,17]. Taken together, CUL3 is involved in the degradation of cyclin E. However, whether FGFR involves in the regulation of CUL3 in HCC proliferation is still not clear.

miRNAs are small, noncoding RNA molecules and they can inhibit the expression of the target genes by triggering mRNA degradation or translational repression through complementary binding to the 3′ untranslated regions of target mRNAs [18]. A recent study shows that miR-141 downregulates the CUL3 level in Hirschsprung’s disease (HSCR) [18], and some studies demonstrate that miR-141 is also highly associated with malignancies such as gastric cancer, colon cancer, nasopharyngeal carcinoma and pancreatic cancer [19,20]. Furthermore, both in vitro and in vivo studies show that transcription factor negatively regulates the promoter activity of miR-141 [19]. Transcription factor NF-κB (p65) is a key regulator of gene expression in inflammatory-related malignant tumors [21], and a previous paper reports that NF-κB (p65) modulates miRNA transcriptional activation [22]. However, whether and how NF-κB (p65) regulates miR-141 in HCC is unclear.

In this study, we used PD173074, an inhibitor of FGFR4, to explore the role of FGFR4 and the underlying mechanism in HepG2 and Hep3B cell lines, and our results suggest that FGFR4 is involved in the proliferation of HCC via ERK/CUL3/cyclin E axis and this finding provides potential therapeutic targets for HCC.

Materials and methods

Materials

PD173074 (S1264), U0126-EtOH (S1102), roscovitine (S1153) and MG132 (S2619) were purchased from Selleck Chemicals (Houston, USA). Epidermal growth factor (EGF) (10605-HNAE) and human FGF19 (10012226-HNAE) were purchased from Sino Biological (Beijing, China). MTT was purchased from Sigma-Aldrich (St. Louis, USA). FGFR4 (#2894), P-FRS2α (Tyr196) (#3864), P-ERK (#4370), ERK (#4695), CDK2 (#2546) and Histone H3 (#4499) antibodies were purchased from Cell Signaling Technology (Boston, USA), and FGFR1 (ab824), ubiquitin (ab7780), CUL3 (ab108407), cyclin E (ab2094) and NF-κB (p65) (ab7970) antibodies were purchased from Abcam (Cambridge, UK). Protein A/G PLUS-
agarose immunoprecipitation reagent (sc-2003) was purchased from Santa Cruz Biotechnology (Dallas, USA).

**Cell culture**

The human hepatoma cell lines HepG2, Hep3B or the human normal liver cell line HL7702 were purchased from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Scientific, Waltham, USA) with 10% fetal bovine serum (FBS) (Thermo Scientific, Waltham, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Hat Biotechnology, Xi’an, China) at 37˚C in 5% CO₂. Cells were starved for 12 h with 2% FBS before treatment with various compounds.

**MTT assay**

HepG2, Hep3B or HL7702 cells were seeded into 96-well plate at 5000 cells/well. After adherence, the cells were treated with different concentrations of PD173074 (0.5, 1, 10, 20 and 50 μM) and, 48 h later, the cells were incubated with MTT solution (500 μg/mL) for 4 h at 37˚C. The formazan was solubilized with DMSO and relative cell viability was measured at 490 nm with a microplate reader (BioTek, Winooski, USA). Growth inhibition in response to various concentrations of PD173074 was calculated using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA, USA).

**Colony survival assay**

Colony survival assay was carried out according to previously published protocol with some modifications [23]. In briefly, HepG2 or Hep3B cells were seeded into 12-well plate at 800 cells/well. Then the cells were treated with different concentrations of PD173074. After forming colonies in the complete DMEM without PD173074 for another 10–14 days. The colonies were clearly visible and countable and, then, they were fixed and stained with crystal violet. Colonies comprising more than 50 cells were enumerated and images were captured with an inverted fluorescence microscope (Nikon, Tokyo, Japan).

**EdU (5-Ethynyl-2'- deoxyuridine) incorporation assay**

HepG2 or HL7702 cells were seeded into 96-well plate at 5000 cells/well. Cell proliferation was determined using the Cell-Light™ EdU Apollo®567 In Vitro Imaging Kit (RiboBio Co. Ltd., Guangzhou, China) according to the manufacturer’s instruction. In brief, after PD173074 treatment for 48 h, cells were fixed with 4% paraformaldehyde and then were permeabilized with 0.5% Triton X-100. After blocking with 2 mg/mL glycine, the cells were washed with PBS and then were incubated with Apollo reaction buffer B at room temperature. 30 min later, the cells were washed and incubated with Hoescht reaction buffer for 10 min at room temperature. Finally, the cells were washed again and then observed under inverted fluorescence microscope.

**Cell cycle analysis**

HepG2, Hep3B or HL7702 cells were seeded into a 6-well plate at 2×10⁵ cells/well. The cells were treated with different concentrations of PD173074 (0.5, 1, 10 μM). 48 h later, the cells were collected, washed and then fixed with cold ethanol (70% v/v) for 2 h at 4˚C. After fixation, the cells were treated with 50 μg/mL propidium iodide (Sigma-Aldrich, St. Louis, USA) and
100 μL RNase A (100 μg/mL) for 30 min in the dark at 4˚C. Finally, the cell cycle was detected by flow cytometry (Becton Dickinson, Franklin Lakes, USA).

**Western blot**

Western blot was performed according to standard protocol. In brief, total proteins were extracted with RIPA buffer (HEART, Xi’an, China). 30 μg of samples were loaded for electrophoresis and then transferred onto PVDF membrane (Millipore, Billerica, USA). After transferring, the membrane was blocked with 5% skimmed milk and, then, incubated with primary antibody overnight at 4˚C. The next day, the membrane was washed with TBST and then incubated with HRP-conjugated secondary antibody at 37˚C. 1 h later, the membrane was washed again and imaged using Immobilon western chemiluminescent HRP substrate (Millipore, Billerica, USA).

**RT-qPCR**

Total RNA was isolated using RNAfast200 reagent (Xifeng Biotechnology, Xi’an, China) and then was reverse-transcribed using PrimeScript RT reagent kit with gDNA Eraser (Takara, Shiga, Japan) or Mir-X miRNA first-strand synthesis kit (Takara, Shiga, Japan) for miR-141 (including an internal control: U6). Finally, RT-qPCR was performed using SYBR Green real-time PCR master mix (Toyobo, Osaka, Japan) and the relative expression was assessed using the $2^{-\Delta\Delta Ct}$ method. The sequences for all primers are as follows:

- cyclin E-F: 5’-GCCATTCTCATCGGGTCCTC-3’
- cyclin E-R: 5’-TCGGTACCACAGGGTCACCA-3’
- CUL3-F: 5’-GGAAGGAAAACAGGGAAGGTG-3’
- CUL3-R: 5’-ACATAGGAAAGGCACACAAAGGA-3’
- GAPDH-F: 5’-GCACCGTCAAGGCTGAGAAC-3’
- GAPDH-R: 5’-TGGTGAAGACGCCAGTGGA-3’
- hsa-miRNA-141-3p: 5’-AACACTGTCTGGTAAAGATGG-3’

**Co-ImmunoPrecipitation (Co-IP)**

HepG2 or Hep3B cells were seeded into 10 cm dish and then were treated with 2 μM PD173074. 24 h later, total proteins were lysed with RIPA buffer (HEART, Xi’an, China). 30 min later, the lysis was spun down and the supernatant was collected. Then, the primary antibody was added into the supernatant and the mixture was incubated on rotator at 4˚C. 24 h later, protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, Dallas, USA) were added and the mixture was incubated at 4˚C. 4 h later, the mixture was pelleted and washed 4 times with RIPA buffer. Finally, the pellet was eluted using electrophoresis sample buffer and the target protein was detected using corresponding primary antibodies by Western blot.

**siRNA silencing**

All siRNAs were purchased from GenePharma (Shanghai, China) and were transfected using Lipofectamine 2000 (Invitrogen) according to standard protocol.

The sequences for all siRNAs are as follows:

1-CUL3-(sense): 5’-GCUUGGAAUGAUCAUCAAATT-3’,
1-CUL3-(antisense): 5′-UUUGAUGAUCAUUCCAAGCTT-3′;
2-CUL3-(sense): 5′-CCAGCCAGAAAGACUAUTT-3′,
2-CUL3-(antisense): 5′-AUAGCUUCCAGUGCUUUGTT-3′;
1-NF-κB (p65)-(sense): 5′-GCUAUUUCUCCCUACCAGCTT-3′,
1-NF-κB (p65)-(antisense): 5′-AGCUGGUAGGGAGAAUAGCTT-3′;
2-NF-κB (p65)-(sense): 5′-GCUCGCCUAUGAGCUUGUTT-3′,
2-NF-κB (p65) (antisense): 5′-ACAGUCAUCAUAGGCGACCTT-3′.

Transfection

miRNA inhibitor was synthesized and purified by GenePharma (Shanghai, China). Transfection was performed with lipofectamine 2000 (Invitrogen). miR-141 inhibitor was transfected at 200 nM.

Nuclear/cytoplasmic fractionation

The cytoplasmic/nuclear protein extraction kit (Beyotime Biotechnology, Wuhan, China) was used to isolate cytoplasmic/nucleus protein. In brief, first, the cells were pelleted, washed and then dissolved in reagent A. After 5 s vortex, the tubes were incubated for 12 min on ice. Next, reagent B was added and the tubes were vortex for 5 s again and then incubated on ice. 1 min later, the samples were immediately centrifuged for 5 min at 14,000×g at 4˚C and the supernatant was transferred into another new tube and frozen for further analysis (Cytoplasmic fraction). Then, the remaining supernatant was decanted and the pellet was resuspended in reagent C (nuclear protein extraction). After another vortex for 30 min, the tubes were centrifuged for 10 min at 14,000×g, and the supernatant was transferred to a new tube for further analysis (Nuclear fraction). Finally, the cytoplasmic/nuclear fractions were used to perform Western blot for the detection of NF-κB (p65) level.

Statistical analysis

The data represent the mean±standard deviations (SD) and were analyzed using GraphPad Prism 7.0. An unpaired Student’s t-test was used for comparison between two groups. For multiple comparisons, data were analyzed by one-way ANOVA with Bonferroni’s post hoc test. A P < 0.05 was considered statistically significant.

Results

PD173074 induces G1 accumulation and suppresses proliferation in HCC cells

We first detected the effect of PD173074 on the viability of HepG2, Hep3B and HL7702 cells by MTT assay. The results showed that it suppressed the viability of all cell lines, and HepG2 and Hep3B were more sensitive to PD173074 compared with HL7702 (Fig 1A). The colony formation of HepG2 and Hep3B cells was significantly suppressed and the number of the colonies was declined (Fig 1B). We then performed an EdU-incorporation assay and found that PD173074 significantly decreased the number of EdU+ cells in HepG2 cells compared with HL7702 cells (Fig 1C). To further explore the effect of PD173074 on cell cycle, we performed flow cytometry and the results showed that, with the increase of the concentration, PD173074
Fig 1. PD blocks G1/S transition and suppresses the proliferation in HCC cells. (A) Cell viability was measured by MTT assay in HepG2, Hep3B and HL7702 cells, and (B) cell proliferation was determined by colony formation assay in HepG2 and Hep3B cells after treating with PD (n = 5). (C) The EdU proliferation assay was performed after PD treatment in HepG2 or HL7702 cells. The red fluorescent cells were those in the S phase of mitosis, and the blue fluorescent cells represented all of the cells (n = 5). After PD treatment, cell cycles of (D) HepG2, (E) Hep3B and (F) HL7702 were analyzed by flow cytometry. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, #P < 0.05, ####P < 0.001.

PD: PD173074.

https://doi.org/10.1371/journal.pone.0234708.g001
treatment resulted in the gradual accumulation of G1 phase in both HepG2 and Hep3B cells (Fig 1D and 1E). However, we did not observe any changes in HL7702 cells (Fig 1F).

**PD173074 blocks FGFRs-mediated FRS2α-ERK pathway in HCC cells**

PD173074 is known to be a selective inhibitor of FGFR1 [24], but can block breast cancer cell proliferation via the FGFR4 signaling pathway [25]. There was no detectable FGFR1 in HepG2, Hep3B and HL7702 cells (S1A Fig). However, FGFR4 was overexpressed in HepG2 and Hep3B cells, and there was little detectable FGFR4 in HL7702 cells (S1A Fig). FGFRs activation upregulates a series of downstream signaling molecules, including P-FRS2α which can activate the MAPK pathway and finally enhances cell proliferation [26]. We treated the cells with different concentrations of PD173074 and found that P-FRS2α and P-ERK levels were markedly decreased in HepG2 cells while a slight decrease in HL7702 cells (Fig 2A). We then treated these cells with 2 μM of PD173074 with different time incubation and the data showed that, compared with control (0 h), PD173074 significantly decreased P-FRS2α and P-ERK level at the timepoints of 8, 16 and 24 h in HepG2 cells while no obvious changes were observed in HL7702 cells (Fig 2B). To further confirm these data, we treated these cells with FGF19, a fibroblast growth factor that interacts with FGFR and activates FGFR activity, and found that FGF19 increased the levels of P-FRS2α and P-ERK and PD173074 significantly attenuated its effect in HepG2 cells (Fig 2C). In addition, similar as ERK inhibitor U0126, PD173074 also attenuated the phosphorylation of ERK in HepG2 cells (S1B Fig). Meanwhile, EGF alone remarkably increased the level of P-ERK and PD173074 blocked this effect in HepG2 cells (S1B Fig).

**PD173074 decreases cyclin E and CDK2 levels in HCC cells**

Cyclin E and CDK2 are important regulators of the G1/S checkpoint during cell cycle progression and our data above showed that PD173074 treatment led to a marked increase in G1-accumulated HCC cells (Fig 1D and 1E). So we also detected the protein levels of cyclin E and CDK2 and the results revealed that, compared with HL7702 cells, their levels were apparently attenuated after treating with different concentrations of PD173074 (Fig 2A) or with different time incubation (Fig 2B). We also treated these cells with FGF19 and found FGF19 treatment led to the upregulation of cyclin E and CDK2 protein levels and PD173074 blocked its effect (Fig 2C). To convince these findings, we utilized, the CDK2 inhibitor, roscovitine to explore the protein levels of cyclin E and CDK2 and, expectedly, either PD173074 or roscovitine attenuated their levels (S1C Fig).

**Upregulation of CUL3 mRNA and protein stimulates cyclin E ubiquitination following PD173074 treatment in HCC cells**

We detected the mRNA level of cyclin E following PD173074 treatment in HepG2 and Hep3B cells, but no changes were found (S2A Fig). However, PD173074 induced ubiquitination in HepG2 and Hep3B cells (Fig 3A) and MG132, an inhibitor of proteasome-mediated proteolysis, caused the accumulation of cyclin E in HepG2 and Hep3B cells (Fig 3B). These results suggest that the degradation of cyclin E is regulated by ubiquitin-dependent proteolytic pathway. Furthermore, Co-IP results showed that PD173074 induced the formation of CUL3/cyclin E complex (Fig 3C). Western blot and RT-qPCR results revealed that PD173074 significantly upregulated the mRNA (Fig 3D) and protein (Fig 3E) levels of CUL3. Besides, CUL3 knockdown by siRNA increased the cyclin E protein levels in both HepG2 cells (Fig 3F) and Hep3B cells (Fig 3H), and slightly decreased their G1 phase respectively. Importantly, PD173074
rescued the effect of CUL3 knockdown on the cell cycle program in HepG2 (Fig 3G) and Hep3B (Fig 3I).

PD173074 upregulates CUL3 via miR-141 in HCC cells

Tang et al. reported that miR-141 negatively regulated CUL3 level in Hirschsprung's disease [18] and the transcription factor NF-κB (p65) was involved in miRNA transcriptional activation in lung cancer [22]. In accordance with the Tang’s results, miR-141 inhibitor transfection resulted in a significant increase in CUL3 mRNA levels (Fig 4A). Moreover, PD173074 decreased miR-141 level in both HepG2 and Hep3B cells (Fig 4B). These data suggest that miR-141 also negatively regulates CUL3 levels in HepG2 and Hep3B cells. Furthermore, we performed bioinformatical analysis (Ensembl genome browser: http://grch37.ensembl.org/Homo_sapiens/Transcript/Exons?db=core;g=ENSG00000207708;r=12:7073260-7073354;t=ENST00000384975; The JASPAR database: http://jaspar.binf.ku.dk/cgi-bin/jaspar_db.pl) and found that miR-141 harbors NF-κB-binding sites located from −87 to −97-bp upstream of the miR-141 initiating site (Fig 4C). Then, we detected the cytoplasmic and nuclear protein levels of NF-κB (p65) and found PD173074 decreased the nuclear NF-κB while no obvious changes were found in cytoplasmic fraction (Fig 4D). To convince these findings, we transfected HepG2 (Fig 4E) and Hep3B cells (Fig 4H) with siRNA targeting NF-κB and found significant decreases in miR-141 level (Fig 4F and I) and inhibited cell viability (Fig 4G and 4J). Furthermore, PD173074 treatment after NF-κB knockdown revealed stronger inhibitory
effects on miR-141 expression (Fig 4F and 4I) and the cell viability (Fig 4G and 4J) in HepG2 and Hep3B cells. Besides, EGF induced ERK phosphorylation and led to the increase in NF-κB (p65) and U0126 decreased ERK phosphorylation and NF-κB (p65) level (S2B Fig).

Discussion

Although the FGFR signaling pathway plays a fundamental role in the organogenesis of the nervous system, tissue repair and inflammation, 7.1% of all tumor types have genetic alterations in the FGF-FGFR axis [27]. Highly expressed FGFR4 in the carcinoma tissues is correlated with HCC progression [3–6] and FGFR4 overexpression has been identified as an oncogenic driver in a subset of patients with HCC. However, the underlying mechanism remains unclear. So, in this study, we aimed to explore the role of FGFR4 and the underlying mechanism in HCC.

In vivo studies showed that PD173074 treatment significantly decreased tumor volume [28,29]. Although PD173074 is always used as FGFR1 inhibitor [30], it can also block cancer cell proliferation via the FGFR4 signaling pathway [25]. Our results revealed that there was no detectable FGFR1 while FGFR4 was overexpressed in HepG2 and Hep3B cells. Inhibitor-mediated inactivation of FGFR4 has a stronger inhibitory effect on cell proliferation and G1 phase arrest in HCC cells. Therefore, PD173074, a tyrosine kinase inhibitor, may function in HepG2 and Hep3B by targeting FGFR4 and our data demonstrate that PD173074 affects G1/S checkpoint and inhibits cell proliferation largely via repressing FGFR4 activity in these HCC cells.

Compared with surrounding normal tissue, cyclin E is highly expressed in the majority of liver cancers [12]. Cyclin E is an important regulator in G1/S checkpoint and a series of evidence shows that cyclin E is involved in HCC progression [31,32]. PD173074 has a strong
inhibitory effect on cyclin E protein level in HCC cells, suggesting that the inhibitory effect of PD173074 on G1 phase and S phase is due to the downregulation of cyclin E protein. However, PD173074 does not affect the mRNA level of cyclin E in HepG2 and Hep3B cells. We also observed PD173074 induced ubiquitination and this suggests ubiquitin proteasome system is implicated in cyclin E protein degradation. CUL3 is an E3 ligase which is strongly involved in DNA synthesis and the formation of micronuclei, and loss of CUL3 in hepatocytes can result in upregulation of cyclin E although this phenomenon is also showed in a large series of human liver cancers [16,17]. In this study, PD173074 caused the upregulation of CUL3 mRNA and protein levels and induced the direct binding of CUL3 to cyclin E, which promoted cyclin E turnover. Furthermore, CUL3 knockdown facilitated the G1/S phase transition and PD173074 rescued this effect. In vitro and in vivo studies have proven that CUL3 is involved in free cyclin E degradation [16,33]. Taken together, FGFR4 overexpression may promote cell

Fig 4. PD decreases miR-141 levels and the ERK/NF-kB (p65) signaling pathway. (A) HepG2 and Hep3B cells were transfected with miR-141 inhibitor and then RT-qPCR was used to determine CUL3 mRNA level (n = 5). (B) Effects of PD (2 μM) for 24 h on miR-141 level were also detected by RT-qPCR (n = 5). (C) Possible NF-kB (p65) target sites in the miR-141 coding region was predicted based on the JASPAR database. (D) Effects of PD on cytoplasmic/nuclear NF-kB (p65) protein level were determined by Western blot. Effects of NF-kB knockdown on NF-kB (p65) protein level were determined by Western blot respectively in (E) HepG2 and (H) Hep3B cells. Effects of NF-kB knockdown alone or combination with PD treatment on miR-141 level (F, I) and cell viability (G, J) were measured by RT-qPCR and MTT assay respectively in HepG2 (F, G) and Hep3B (I, J) (n = 5). "P < 0.05, **P < 0.01, ***P < 0.001. PD: PD173074, Ctrl: control.

https://doi.org/10.1371/journal.pone.0234708.g004
proliferation by upregulating cyclin E protein level and inducing cyclin E/CDK2 complex formation which finally stimulates G1/S transition.

An interesting issue is to determine how the inhibitory activity of FGFR4 caused the increase in CUL3 mRNA and protein levels. Tang et al. report that miR-141 can target CUL3 and result in its downregulation in HSCR [18]. Here, PD173074 inhibited miR-141 and miR-141 inhibitor transfection increased CUL3 mRNA in HCC cells, suggesting that miR-141 also participates in regulating CUL3 expression in HCC cells. miRNA genes are regulated in a similar way as that of coding genes and nuclear transcriptional regulatory factors can regulate the promoter activity of miR-141 [34–37]. NF-κB (p65), a transcription factor, plays an important role in the regulation of normal cell proliferation and is aberrantly expressed in many human cancers, and recent studies suggest NF-κB (p65) is involved in the expression of miRNA [37,38]. From bioinformatical analysis, miR-141 is the target of NF-κB (p65). Therefore, we further explored the effect of PD173074 on miR-141 and NF-κB (p65) and possible mechanism. The data showed that PD173074 decreased NF-κB (p65) level in the nucleus which regulates gene transcription directly. Furthermore, NF-κB (p65) knockdown led to the decrease of miR-141 level and cell viability and PD173074 enhanced this effect. Besides, ERK phosphorylation upregulated NF-κB (p65) protein level, and ERK dephosphorylation downregulated NF-κB (p65) level, indicating PD173074 may decrease nuclear NF-κB (p65) level via the MAPK pathway. Taken together, these results suggest that NF-κB (p65) may involve in the

![Fig 5. Schematic of PD173074-mediated G1 phase arrest of HepG2 cells.](https://doi.org/10.1371/journal.pone.0234708.g005)
proliferation regulation of HCC by targeting miR-141 which targets CUL3, and the activation of the FGFR4 signaling pathway induces nuclear NF-κB (p65) expression via ERK-mediated signaling transduction in HCC.

In conclusion, FGFR4 is involved in the proliferation of HCC cells by ERK/CUL3/cyclin E signaling pathway and these findings may provide a potential theoretical basis for treatment by targeting FGFR4 in HCC (Fig 5).

Supporting information

S1 Fig. (A) Expression of FGFR1 and FGFR4 in HepG2, Hep3B and HL7702 were determined by Western blot analysis with specific antibodies (n = 3). (B) HepG2 cells were treated with U0126 (2 μM, 4 h), EGF (20 ng/mL, 2 h) or PD (2 μM, 24 h), and ERK phosphorylation was measured by Western blot (n = 3). (C) HepG2 cells were treated with Rosc (4 μM) or PD (2 μM) for 24 h, and cyclin E and CDK2 protein levels were measured by Western blot (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Ctrl: control, PD: PD173074, Rosc: roscovitine. (TIF)

S2 Fig. (A) HepG2 and Hep3B cells were treated with PD (2 μM) for 24 h, and RT-qPCR was performed to analyze cyclin E mRNA level. Data were normalized by GAPDH level (n = 5). (B) Western blot analysis of NF-κB (p65) levels in ctrl, EGF- or U0126-treated cells after 2 h and 4 h of treatment, respectively. *P < 0.05, **P < 0.01. PD: PD173074, Ctrl: control, NC: Negative Control. (TIF)

S1 Raw images.
(PDF)

Acknowledgments

The authors would like to thank Dr. Ying Guo for critical reading of the manuscript.

Author Contributions

Data curation: Chuchu Qiao, Pengyu Ma.
Formal analysis: Chuchu Qiao.
Funding acquisition: Tao Zhang, Xinshe Liu.
Investigation: Chuchu Qiao.
Methodology: Chuchu Qiao, Pengyu Ma.
Project administration: Tao Zhang, Xinshe Liu.
Resources: Chuchu Qiao, Hongyan Qian, Tingting Zhao, Xinshe Liu.
Software: Chuchu Qiao, Jue Wang, Tingting Zhao.
Supervision: Sicen Wang, Tao Zhang, Xinshe Liu.
Validation: Chuchu Qiao.
Visualization: Chuchu Qiao.
Writing – original draft: Chuchu Qiao.
Writing – review & editing: Chuchu Qiao.
References

1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116–129. https://doi.org/10.1038/nrc2780 PMID: 20094046

2. Porta R, Borea R, Coelho A, Khan S, Araujo A, Reclusa P, et al. FGFR4 and TGF-β1 Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Prognosis. Int J Med Sci. 2013; 10(13):1868–1875. https://doi.org/10.7150/ijms.8868 PMID: 24324363

3. Chen Z, Bao X, Xia Q, Jiang S, Cao R, et al. FGFR4 and TGF-β1 Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Prognosis. Int J Med Sci. 2013; 10(13):1868–1875. https://doi.org/10.7150/ijms.8868 PMID: 24324363

4. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009; 50(1):118–127. https://doi.org/10.1016/j.jhep.2008.08.015 PMID: 19008009

5. Vainikka S, Joukov V, Wennstrom S, Bergman M, Pelicci PG, Alitalo K. Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J Biol Chem. 1994; 269(28):18320–18326. PMID: 7518429

6. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One. 2011; 6(3):e17866. https://doi.org/10.1371/journal.pone.0017866 PMID: 21437243

7. Icard P, Fournel L, Wu Z, Alifano M, Lincet H. Interconnection between Metabolism and Cell Cycle in Cancer. Trends Biochem Sci. 2019; 44(6):490–501. https://doi.org/10.1016/j.tibs.2018.12.007 PMID: 30655165

8. Poon RY, Hunter T. Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science. 1995; 270(5233):90–93. https://doi.org/10.1126/science.270.5233.90 PMID: 7569954

9. Keenan SM, Bellone C, Baldassare JJ. Cyclin-dependent kinase 2 nucleocytoplasmic translocation is regulated by extracellular regulated kinase. J Biol Chem. 2001; 276(25):22404–22409. https://doi.org/10.1074/jbc.M100409200 PMID: 11304535

10. Desai D, Wessling HC, Fisher RP, Morgan DO. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDC2K. Mol Cell Biol. 1995; 15(1):345–350. https://doi.org/10.1128/mcb.15.1.345 PMID: 7799941

11. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokochi K, et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 2003; 37(3):534–543. https://doi.org/10.1053/jhep.2003.50112 PMID: 12601350

12. Scheffner M, Smith S, Jentsch S. The Ubiquitin-Conjugation System: Springer US. 1998; 179–207p.

13. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997; 3(2):222–225. https://doi.org/10.1038/nm0297-222 PMID: 9108243

14. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. 2001; 413(6853) :316–322.

15. McEvoy JD, Kossatz U, Malek N, Singer JD. Constitutive turnover of cyclin E by Cul3 maintains quiescence. Mol Cell Biol. 2007; 27(10):3651–3666. https://doi.org/10.1128/MCB.00720-06 PMID: 17393933

16. Singer JD, Gurian-West M, Clurman B, Roberts JM. Culin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev. 1999; 13(18):2375–2387. https://doi.org/10.1101/gad.13.18.2375 PMID: 10500995

17. Tang W, Qin J, Tang J, Zhang H, Zhou Z, Li B, et al. Aberrant reduction of MiR-141 increased CD47/CUL3 in Hirschsprung’s disease. Cell Physiol Biochem. 2013; 32(8):1655–1667. https://doi.org/10.1159/000356601 PMID: 24334875

18. Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016; 7:e2156. https://doi.org/10.1038/cddis.2016.64 PMID: 27018877

19. van Jaarsveld MT, Heijerman J, Boersma AW, van Kuik PF, van Ilcken WF, Despierre E, et al. mir-141 regulates KEAP1 and modulates caspatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32 (36):4284–4293. https://doi.org/10.1038/onc.2012.435 PMID: 23045278
21. Naugler WE, Karin M. NF-kappaB and cancer—identifying targets and mechanisms. Curr Opin Genet Dev. 2008; 18(1):19–26. https://doi.org/10.1016/j.gde.2008.01.020 PMID: 18440219

22. Jeon YJ, Middleton J, Kim T, Laganà A, Piovano C, Secchiero P, et al. A set of NF-κB-regulated micro-RNAs acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci USA. 2015; 112(26): E3355. https://doi.org/10.1073/pnas.1504630112 PMID: 26080425

23. Shi X, Zhu M, Gong Z, Yang T, Wang J, et al. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/ACT and MAPK/ERK1/2 signaling pathways. Food Chem Toxicol. 2019; 136:110960. https://doi.org/10.1016/j.fct.2019.110960 PMID: 31726078

24. Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N, et al. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013; 109(8):2248–2258. https://doi.org/10.1038/bjc.2013.550 PMID: 24045665

25. Koziczak M, Hynes NE. Cooperation between fibroblast growth factor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem. 2004; 279(48):50004–50011. https://doi.org/10.1074/jbc.M404252200 PMID: 15377668

26. Persaud A, Alberts P, Hayes M, Guettler S, Clarke I, Sicheri F, et al. Nedd4-1 binds and ubiquitylates activated FGFR1 to control its endocytosis and function. EMBO J. 2011; 30(16):3259–3273. https://doi.org/10.1038/emboj.2011.234 PMID: 21765395

27. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016; 22(1):259–267. https://doi.org/10.1158/1078-0432.CCR-14-3212 PMID: 26373574

28. Ezzat S, Huang P, Dackiw A, Asa SL. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res. 2005; 11(3):1336–1341. PMID: 15709206

29. Okimoto T, Takechi M, Isobe T, Kim J, Kim HS, Shim JJ, et al. Critical role of the fibroblast growth factor signalling pathway in Ewing’s sarcoma octamer-transcription factor binding transcription factor 4-mediated cell proliferation and tumorigenesis. Respir Res. 2019; 286(22):4443–4472.

30. Bae JM, Wen X, Kim T-S, Kwak Y, Cho N-Y, Lee HS, et al. Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers. Cancer Res Treat. 2019; 52(1):74–84. https://doi.org/10.4143/crt.2019.062 PMID: 31096734

31. Knoblich JA, Sauer K, Jones L, Richardson H, Saint R, Lehner CF, et al. Cyclin E controls S phase progression and its down-regulation during Drosophila embryogenesis is required for the arrest of cell proliferation. Cell. 1994; 77(1):107–120. https://doi.org/10.1016/0092-8674(94)90239-9 PMID: 8165878

32. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology. 1999; 30(1):90–99. https://doi.org/10.1002/hep.510300114 PMID: 10385644

33. Clurman BE, Sheaff RJ, Thress K, Grou din E, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996; 10 (16):1979–1990. https://doi.org/10.1101/gad.10.16.1979 PMID: 8769642

34. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, et al. A CAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA. 2005; 102(45):16426–16431. https://doi.org/10.1073/pnas.0508448102 PMID: 16260724

35. Hermeking H. p53 enters the microRNA world. Cancer Cell. 2007; 12(5):414–418. https://doi.org/10.1016/j.ccr.2007.10.028 PMID: 17996645

36. O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):435:839–843.

37. Jayeeta G, Mithun S, Eashita D, Nihar RJ, Nitai PB. Regulation of miR-146a by RelA/NFkB and p53 in ST/HeH(Q111)/Hdh(Q111) cells, a cell model of Huntington’s disease. PLoS One. 2011; 6(8):e23837. https://doi.org/10.1371/journal.pone.0023837 PMID: 21887328

38. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006; 103(33):12481–12486. https://doi.org/10.1073/pnas.0605298103 PMID: 16885212